OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hematology & Oncology is 93. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity	674
Targeting the Wnt/β-catenin signaling pathway in cancer	621
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19	478
Nanomaterials for cancer therapy: current progress and perspectives	466
EZH2: a novel target for cancer treatment	438
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer	357
NK cell-based cancer immunotherapy: from basic biology to clinical development	305
Next generation of immune checkpoint inhibitors and beyond	294
Regulation of PD-L1 expression in the tumor microenvironment	277
Roles of METTL3 in cancer: mechanisms and therapeutic targeting	264
cGAS-STING, an important pathway in cancer immunotherapy	250
Challenges and advances in clinical applications of mesenchymal stromal cells	247
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)	226
RNA sequencing: new technologies and applications in cancer research	226
Cancer vaccines as promising immuno-therapeutics: platforms and current progress	225
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy	223
Isolation and characterization of exosomes for cancer research	209
Combination strategies to maximize the benefits of cancer immunotherapy	206
Dendritic cell biology and its role in tumor immunotherapy	203
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy	196
Immunosenescence: a key player in cancer development	195
Targeting mutant p53 for cancer therapy: direct and indirect strategies	193
Targeting hypoxic tumor microenvironment in pancreatic cancer	192
Novel therapies emerging in oncology to target the TGF-β pathway	191
Recent advances in CAR-T cell engineering	190

Neutrophils in cancer carcinogenesis and metastasis	189
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling	182
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia	178
Applications of single-cell sequencing in cancer research: progress and perspectives	177
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells	177
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response	174
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)	174
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions	170
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis	167
m6A-binding proteins: the emerging crucial performers in epigenetics	166
Liquid biopsy: current technology and clinical applications	164
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma	161
Oncolytic viruses for cancer immunotherapy	158
Recent advances in therapeutic strategies for triple-negative breast cancer	157
Emerging therapeutic agents for advanced non-small cell lung cancer	156
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy	155
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study	154
RNA-binding proteins in tumor progression	150
Targeting CD47 for cancer immunotherapy	147
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research	145
Targeting MCL-1 in cancer: current status and perspectives	142
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti	142
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019	142
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway	140
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	139
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy	136
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy	133
MEK inhibitors for the treatment of non-small cell lung cancer	132
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	132
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets	127
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target	126
Antibody–drug conjugates in solid tumors: a look into novel targets	125
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends	125
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment	125
Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis	124
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies	123
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	122
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019	122
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update	121
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy	119
Modeling neoplastic disease with spheroids and organoids	117
HMGB1 in inflammation and cancer	117
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape	116
XPO1-dependent nuclear export as a target for cancer therapy	114
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy	114
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1	114
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017	110
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies	109
Emerging agents that target signaling pathways in cancer stem cells	109
Targeting autophagy to overcome drug resistance: further developments	106

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy	106
tRNA-derived RNA fragments in cancer: current status and future perspectives	105
BCMA-targeted immunotherapy for multiple myeloma	105
Exploring immunotherapy in colorectal cancer	105
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin	104
How to select IgG subclasses in developing anti-tumor therapeutic antibodies	103
The management of metastatic GIST: current standard and investigational therapeutics	102
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential	100
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands	100
Role of lysosomes in physiological activities, diseases, and therapy	99
Emerging agents and regimens for AML	99
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies	98
Mesenchymal stem/stromal cells in cancer therapy	98
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions	97
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation	96
Expression patterns of immune checkpoints in acute myeloid leukemia	95
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward	94
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies	94
The potential role of N7-methylguanosine (m7G) in cancer	93